Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit
October 06 2022 - 8:00AM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
oncology company developing first-in-class1 therapeutics that
combine both targeted and immune-mediated mechanisms, today
announced that Dara Burdette, Ph.D., Senior Director of Discovery
Research at Tempest, will present on the company’s TREX1 pipeline
asset and will serve as chairperson for the “New Approaches to
Solid Tumor Targeting” session at the Emerging Technologies for IO
Targeting and Discovery Summit taking place October 13-14, 2022 in
Boston, MA.
TREX1 Presentation
Dr. Burdette’s presentation will describe the
company’s approach to identify and characterize novel small
molecule inhibitors of the 3’-5’ DNA repair exonuclease, TREX1.
TREX1 inhibits cGAS/STING signaling and is induced in tumor cells
due to genetic instability or therapeutic intervention. Tempest’s
program aims to generate an anti-tumor response through selectively
activating the STING pathway in advanced metastatic cancers with
orally available small molecule inhibitors of TREX1.
Presentation details:
Title: |
Small Molecules Targeting the 3’-5’ DNA Repair Exonuclease TREX1
SelectivelyActivate the STING Pathway and Induce Tumor-Specific
Immunity |
Date: |
Thursday, October 13, 2022 |
Time: |
2:40 p.m. EDT |
TPST-1495 Presentation
In addition, Nicholas DeVito, M.D., a medical
oncologist and medical instructor in the laboratory of Dr. Brent
Hanks, M.D., Ph.D. at Duke University School of Medicine, will be
giving a presentation describing pre-clinical results with
TPST-1495, Tempest’s clinical-stage dual inhibitor of the EP2 and
EP4 prostaglandin E2 receptors, in mice bearing tumors with
designated gene expression profiles.
Presentation details:
Title: |
Understanding Tumor-Mediated Immune Evasion to Develop Biomarkers
toward Rational Therapeutic Combinations |
Date: |
Wednesday, October 12, 2022 |
Time: |
8:40 a.m. EDT |
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
oncology company advancing small molecules that combine both
tumor-targeted and immune-mediated mechanisms with the potential to
treat a wide range of tumors. The company’s two novel clinical
programs are TPST-1120 and TPST-1495, antagonists of PPARα and
EP2/EP4, respectively. Both programs are advancing through clinical
trials designed to study the agents as monotherapies and in
combination with other approved agents. Tempest is also developing
an orally available inhibitor of TREX1, a target that controls
activation of the cGAS/STING pathway. Tempest is headquartered in
South San Francisco. More information about Tempest can be found on
the company’s website at www.tempesttx.com.
Investor Contacts:Sylvia WheelerWheelhouse Life
Science Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
1 If approved by the FDA
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Jul 2024 to Jul 2024
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Jul 2023 to Jul 2024